211 related articles for article (PubMed ID: 9135021)
1. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.
Augenlicht LH; Wadler S; Corner G; Richards C; Ryan L; Multani AS; Pathak S; Benson A; Haller D; Heerdt BG
Cancer Res; 1997 May; 57(9):1769-75. PubMed ID: 9135021
[TBL] [Abstract][Full Text] [Related]
2. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH
Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570
[TBL] [Abstract][Full Text] [Related]
3. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene.
Donzelli M; Bernardi R; Negri C; Prosperi E; Padovan L; Lavialle C; Brison O; Scovassi AI
Oncogene; 1999 Jan; 18(2):439-48. PubMed ID: 9927200
[TBL] [Abstract][Full Text] [Related]
5. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
6. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of c-myc and transforming growth factor-alpha messenger RNA expression in poorly differentiated and well-differentiated colon carcinoma cells during the establishment of a quiescent state.
Mulder KM
Cancer Res; 1991 May; 51(9):2256-62. PubMed ID: 2015589
[TBL] [Abstract][Full Text] [Related]
8. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
9. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
10. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of the c-myc gene without gene amplification in human lung cancer and colon cancer cell lines.
Yoshimoto K; Hirohashi S; Sekiya T
Jpn J Cancer Res; 1986 Jun; 77(6):540-5. PubMed ID: 3089986
[TBL] [Abstract][Full Text] [Related]
12. Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression.
Greco C; Alvino S; Buglioni S; Assisi D; Lapenta R; Grassi A; Stigliano V; Mottolese M; Casale V
Anticancer Res; 2001; 21(5):3185-92. PubMed ID: 11848471
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade.
Mahdy E; Pan Y; Wang N; Malmström PU; Ekman P; Bergerheim U
Anticancer Res; 2001; 21(5):3167-73. PubMed ID: 11848469
[TBL] [Abstract][Full Text] [Related]
14. [Expression, amplification and rearrangement of c-myc gene in human thyroid carcinoma].
Yang Y
Zhonghua Yi Xue Za Zhi; 1991 Jun; 71(6):304-6, 22. PubMed ID: 1667490
[TBL] [Abstract][Full Text] [Related]
15. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.
Akervall J; Bockmühl U; Petersen I; Yang K; Carey TE; Kurnit DM
Clin Cancer Res; 2003 May; 9(5):1750-5. PubMed ID: 12738730
[TBL] [Abstract][Full Text] [Related]
16. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract][Full Text] [Related]
17. Genomic instability and apoptosis are frequent in p53 deficient young mice.
Fukasawa K; Wiener F; Vande Woude GF; Mai S
Oncogene; 1997 Sep; 15(11):1295-302. PubMed ID: 9315097
[TBL] [Abstract][Full Text] [Related]
18. Is the presence of distant metastasis associated with c-myc amplification in gastric cancer?
Hajdú J; Kozma L; Kiss I; Szentkereszty Z; Szakáll S; Ember I
Acta Chir Hung; 1997; 36(1-4):119-21. PubMed ID: 9408311
[TBL] [Abstract][Full Text] [Related]
19. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
20. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
